Trial Profile
Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2018
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 24 Oct 2018 Interim analysis results (data cut off date: 5 Nov 2017; n=3929) assessing incidence of serious infection events in patients with rheumatoid arthritis receiving tofacitinib, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 24 Oct 2018 Interim analysis results of safety data (data-cut off date: 5 Nov 2017 (6 month), n=3929) from this trial, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 16 Jun 2018 Results of 6- month interim analysis (n=3929 , data cut off: 5 Nov 2017) presented at the 19th Annual Congress of the European League Against Rheumatism